Progress of implementation of the World Health Organization strategy for HIV drug resistance control in Latin America and the Caribbean

Ravasi, Giovanni; Jack, Noreen; Alonso Gonzalez, Mónica; Sued, Omar; Pérez-Rosales, María Dolores; Gomez, Bertha; Vila, Marcelo; Del Riego, Amalia; Ghidinelli, Massimo
December 2011
Pan American Journal of Public Health;Dec2011, Vol. 30 Issue 6, p657
Academic Journal
By the end of 2010, Latin America and the Caribbean (LAC) achieved 63% antiretroviral treatment (ART) coverage. Measures to control HIV drug resistance (HIVDR) at the country level are recommended to maximize the efficacy and sustainability of ART programs. Since 2006, the Pan American Health Organization has supported implementation of the World Health Organization (WHO) strategy for HIVDR prevention and assessment through regional capacity-building activities and direct technical cooperation in 30 LAC countries. By 2010, 85 sites in 19 countries reported early warning indicators, providing information about the extent of potential drivers of drug resistance at the ART site. In 2009, 41.9% of sites did not achieve the WHO target of 100% appropriate first-line prescriptions; 6.3% still experienced high rates (> 20%) of loss to follow-up, and 16.2% had low retention of patients (< 70%) on first-line prescriptions in the first year of treatment. Stock-outs of antiretroviral drugs occurred at 22.7% of sites. Haiti, Guyana, and the Mesoamerican region are planning and implementing WHO HIVDR monitoring surveys or threshold surveys. New HIVDR surveillance tools for concentrated epidemics would promote further scale-up. Extending the WHO HIVDR lab network in Latin America is key to strengthening regional lab capacity to support quality assured HIVDR surveillance. The WHO HIVDR control strategy is feasible and can be rolled out in LAC. Integrating HIVDR activities in national HIV care and treatment plans is key to ensuring the sustainability of this strategy.


Related Articles

  • Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics. Dimitrov, Dobromir; Boily, Marie-Claude; Mâsse, Benoît R.; Brown, Elizabeth R. // Journal of AIDS & Clinical Research;Special2012, Vol. 3 Issue S, Special section p1 

    Background: The first antiretroviral drug (Truvada) to be used as a pre-exposure prophylaxis (PrEP) in preventing HIV transmission is about to be approved. Behavioral studies suggest that a portion of users may share anti-retroviral drugs with sex partners, family, or friends. Pill sharing will...

  • History and origin of the HIV-1 subtype C epidemic in South Africa and the greater southern African region. Wilkinson, Eduan; Engelbrecht, Susan; de Oliveira, Tulio // Scientific Reports;11/20/2015, p16897 

    HIV has spread at an alarming rate in South Africa, making it the country with the highest number of HIV infections. Several studies have investigated the histories of HIV-1 subtype C epidemics but none have done so in the context of social and political transformation in southern Africa. There...

  • Should Patients with Drug-Resistant HIV-1 Continue to Receive Antiretroviral Therapy? Frenkel, Lisa M.; Mullins, James I. // New England Journal of Medicine;02/15/2001, Vol. 344 Issue 7, p520 

    Editorial. Discusses a study published in the February 15, 2001 issue of the 'New England Journal of Medicine' which demonstrates that among HIV-1 patients with incomplete suppression of viral replication, HIV-1 plasma levels may be significantly lower with antiretroviral than if it were...

  • Genotypic Detection of Resistance to Antiretroviral Therapy (Art): A Brief Review. Suguna, E.; Revathy, A. R.; Gunasundary, T.; Menezes, G. A. // International Journal of Pharmaceutical Sciences Review & Resear;May/Jun2014, Vol. 26 Issue 1, p197 

    Antiretroviral therapy (ART) refers to the use of a combination of three or more Antiretroviral (ARV) drugs to inhibit the replication of Human Immunodeficiency Virus (HIV) and to delay the immune deterioration, in turn to improve the survival rate and quality of life. There has been an increase...

  • Antiretroviral Resistance among HIV-Infected Persons Who Have Died in British Columbia, in the Era of Modern Antiretroviral Therapy.  // Journal of Infectious Diseases;7/15/2004, Vol. 190 Issue 2, p285 

    The article discusses a study on the antiretroviral resistance among HIV-infected persons who have died in British Columbia, Canada in the era of modern antiretroviral therapy. Topics discussed include side effects, illness, and toxicity. In addition, reference is made to a correlation between...

  • The development of drug resistance mutations K103N Y181C and G190A in long term Nevirapine-containing antiviral therapy. Yuncong Wang; Hui Xing; Lingjie Liao; Zhe Wang; Bin Su; Quanbi Zhao; Yi Feng; Pengfei Ma; Jia Liu; Jianjun Wu; Yuhua Ruan; Yiming Shao // AIDS Research & Therapy;2014, Vol. 11, p1 

    Objective We built a cohort study of HIV patients taking long-term first-line Antiretroviral Therapy in 2003. In this assay, we focused on the development of primary drug resistance mutations against Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), K103N, Y181C and G190A. Method The...

  • Improved Prediction of Salvage Antiretroviral Therapy Outcomes Using Ultrasensitive HIV-1 Drug Resistance Testing. Pou, Christian; Noguera-Julian, Marc; Pérez-Álvarez, Susana; García, Federico; Delgado, Rafael; Dalmau, David; Álvarez-Tejado, Miguel; Gonzalez, Dimitri; Sayada, Chalom; Chueca, Natalia; Pulido, Federico; Ibáñez, Laura; Rodríguez, Cristina; Casadellà, Maria; Santos, José R.; Ruiz, Lidia; Clotet, Bonaventura; Paredes, Roger // Clinical Infectious Diseases;Aug2014, Vol. 59 Issue 4, p578 

    Ultrasensitive human immunodeficiency virus type 1 (HIV-1) genotyping predicts salvage antiretroviral therapy (ART) outcomes better than Sanger sequencing. A genotypic sensitivity score <3 by 454 is an independent predictor of virological failure to salvage ART. Ultrasensitive HIV-1 drug...

  • Cellular HIV-1 DNA Levels in Drug Sensitive Strains Are Equivalent to Those in Drug Resistant Strains in Newly- Diagnosed Patients in Europe. Victoria L. Demetriou; David A. M. C. van de Vijver; Ioanna Kousiappa; Claudia Balotta; Clotet, Bonaventura; Zehava Grossman; Louise B. Jørgensen; Snjezana Z. Lepej; Itzchak Levy; Claus Nielsen; Dimitrios Paraskevis; Mario Poljak; Francois Roman; Lidia Ruiz; Jean-Claude Schmidt; Vandamme, Anne-Mieke; Van Laethem, Kristel; Vercauteren, Jurgen; Kostrikis, Leondios G. // PLoS ONE;2010, Vol. 5 Issue 6, p1 

    Background: HIV-1 genotypic drug resistance is an important threat to the success of antiretroviral therapy and transmitted resistance has reached 9% prevalence in Europe. Studies have demonstrated that HIV-1 DNA load in peripheral blood mononuclear cells (PBMC) have a predictive value for...

  • Pretreatment HIV Drug Resistance Increases Regimen Switches in Sub-Saharan Africa. Boender, T. Sonia; Hoenderboom, Bernice M.; Sigaloff, Kim C. E.; Hamers, Raph L.; Wellington, Maureen; Shamu, Tinei; Siwale, Margaret; Maksimos, Eman E. F. Labib; Nankya, Immaculate; Kityo, Cissy M.; Adeyemo, Titilope A.; Akanmu, Alani Sulaimon; Mandaliya, Kishor; Botes, Mariette E.; Ondoa, Pascale; de Wit, Tobias F. Rinke // Clinical Infectious Diseases;12/1/2015, Vol. 61 Issue 11, p1749 

    Background: After the scale-up of antiretroviral therapy (ART) for human immunodeficiency virus (HIV) infection in Africa, increasing numbers of patients have pretreatment drug resistance. Methods: In a large multicountry cohort of patients starting standard first-line ART in six African...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics